Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Patient education materials

Novo Nordisk believes in supporting patients with resources to help them better understand bleeding disorders. These educational materials are available to download, share with patients, or order for your office.

Patient education materials

Novo Nordisk believes in supporting patients with resources to help them better understand hemophilia and rare bleeding disorders. These educational materials are available to download, share with patients, or order for your office.

Bob has hemophilia A with an inhibitor

 

Teach patients the signs and symptoms of internal bleeds

This educational resource may be able to help your patients quickly identify bleeds when and where they happen. Use this tool to help your patients identify breakthrough bleeds which may require treament on-the-go.

Try the Bleed ID Tool
NovoSeven® RT Factor VII Deficiency Brochure
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
NovoSeven® RT Factor VII Deficiency Brochure
A resource designed for patients with CFVIId, with baseline information, signs and symptoms, available treatments and more.
Download
Prescribing Information | Important Safety Information
NovoSeven® RT Glanzmann's thrombasthenia (GT) with Refractoriness to Platelets Brochure
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
NovoSeven® RT Glanzmann's thrombasthenia (GT) with Refractoriness to Platelets Brochure
Information about GT with refractoriness to platelet transfusions, with or without antibodies to platelets.
Download
Prescribing Information | Important Safety Information
NovoSeven® RT MixPro Fact Sheet
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
NovoSeven® RT MixPro Fact Sheet
An overview on how NovoSeven® RT with MixPro® can help patients begin to treat a bleed in just a few steps by using a prefilled syringe to reconstitute.
Download
Prescribing Information | Important Safety Information
Hemophilia Dictionary
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Hemophilia Dictionary
A guide for patients and caregivers, with definitions of common terms and other helpful facts.
Download

Materials available through your Novo Nordisk Representative

The following items are available by contacting your representative:

Demonstration Kit

Demonstration Kit

This kit demonstrates the compact storage size and portability of NovoSeven® RT, and helps you show patients how quick it is to reconstitute a dose of NovoSeven® RT.

Patient Starter Kit

Patient Starter Kit

Patients can practice mixing a dose before they start treatment. This kit includes a sample device, bilingual (English/Spanish) infusion mat, sample kit with test product, introductory brochure, and web key that launches an instructional reconstitution video. The kit comes in a zippered carrying case.

Ready-to-Travel Case

Ready-to-Travel Case

This portable, reusable travel case makes it possible to store supplies at home or while traveling.

To request a Demonstration Kit, Patient Starter Kit or Ready-to-Travel Case, please contact your representative.

Patient advocacy groups.

Hemophilia Federation of America (HFA)

Hemophilia Federation of America (HFA)

Connecting people affected by bleeding disorders to others in their community, while advocating for the development of safe, affordable treatment options. Get more info at http://www.hemophiliafed.org. 

National Hemophilia Foundation (NHF)

National Hemophilia Foundation (NHF)

The largest nonprofit organization dedicated to education, advocacy, and research of inheritable bleeding disorders. Direct patients to find resources at https://www.hemophilia.org. 

World Federation of Hemophilia (WFH)

World Federation of Hemophilia (WFH)

Committed to improving and sustaining excellent care for people with bleeding disorders across the world. Help patients learn more about the WFH by sending them to https://www.wfh.org. 

Product Support for patients

Product Support for patients.

Go to product support
NovoSeven® RT mechanism of action

Find resources and education for health care professionals.

See education for you
NovoSeven® RT vials

Find the dose for your patients.*

Use this dosing calculator

*As a reminder, for US health care professionals only.

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
MixPro® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23NSVN00011 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials